Low-grade inflammation, CoVID-19, and obesity: clinical aspect and molecular insights in childhood and adulthood.
Journal
International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
08
10
2021
accepted:
08
03
2022
revised:
21
02
2022
pubmed:
9
4
2022
medline:
1
7
2022
entrez:
8
4
2022
Statut:
ppublish
Résumé
The new 2019 coronavirus 19 disease (CoVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a serious threat to health systems. As a global health problem, this pandemic poses a huge threat to people and is responsible for significant morbidity and mortality worldwide. On the other hand, obesity has also reached epidemic proportions and poses another challenge to the healthcare system. There is increasing evidence of a strong association between obesity and CoVID-19 disease, but the mechanisms underlying the link between the two remain unclear and the role of obesity also remains to be elucidated. In particular obesity-related low-grade inflammation has been hypothesized as the Achille's heel that could predispose subjects with obesity to a more severe CoVID-19 compared to subjects with normal weight. Hence, we summarized recent evidence on the role of low-grade inflammation in clinical aspects of CoVID-19 in subjects with obesity in both childhood and adulthood. Further, we provide molecular insights to explain this link.
Identifiants
pubmed: 35393519
doi: 10.1038/s41366-022-01111-5
pii: 10.1038/s41366-022-01111-5
pmc: PMC8988546
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1254-1261Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157–60.
pubmed: 32191675
pmcid: 7569573
Collaboration NCDRF. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387:1377–96.
doi: 10.1016/S0140-6736(16)30054-X
WHO. Obesity and overweight. 2016; https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight .
Michalakis K, Goulis DG, Vazaiou A, Mintziori G, Polymeris A, Abrahamian-Michalakis A. Obesity in the ageing man. Metabolism. 2013;62:1341–9.
pubmed: 23831443
doi: 10.1016/j.metabol.2013.05.019
Barrea L, Pugliese G, Framondi L, Di Matteo R, Laudisio D, Savastano S, et al. Does Sars-Cov-2 threaten our dreams? Effect of quarantine on sleep quality and body mass index. J Transl Med. 2020;18:318.
pubmed: 32811530
pmcid: 7432549
doi: 10.1186/s12967-020-02465-y
Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6:944–53.
pubmed: 30389323
pmcid: 6249991
doi: 10.1016/S2213-8587(18)30288-2
Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898–918.
pubmed: 16380542
doi: 10.1161/CIRCULATIONAHA.106.171016
Stefan N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol. 2020;8:616–27.
pubmed: 32559477
doi: 10.1016/S2213-8587(20)30110-8
Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7:313–24.
pubmed: 30174213
doi: 10.1016/S2213-8587(18)30154-2
Donohoe CL, Lysaght J, O’Sullivan J, Reynolds JV. Emerging concepts linking obesity with the hallmarks of cancer. Trends Endocrinol Metab. 2017;28:46–62.
pubmed: 27633129
doi: 10.1016/j.tem.2016.08.004
Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542:177–85.
pubmed: 28179656
doi: 10.1038/nature21363
Kloting N, Bluher M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev Endocr Metab Disord. 2014;15:277–87.
pubmed: 25344447
doi: 10.1007/s11154-014-9301-0
Louwen F, Ritter A, Kreis NN, Yuan J. Insight into the development of obesity: functional alterations of adipose-derived mesenchymal stem cells. Obes Rev. 2018;19:888–904.
pubmed: 29521029
doi: 10.1111/obr.12679
Febbraio MA. Role of interleukins in obesity: implications for metabolic disease. Trends Endocrinol Metab. 2014;25:312–9.
pubmed: 24698032
doi: 10.1016/j.tem.2014.02.004
Reilly SM, Saltiel AR. Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 2017;13:633–43.
pubmed: 28799554
doi: 10.1038/nrendo.2017.90
Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–6.
pubmed: 17167471
doi: 10.1038/nature05482
McLaughlin T, Ackerman SE, Shen L, Engleman E. Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest. 2017;127:5–13.
pubmed: 28045397
pmcid: 5199693
doi: 10.1172/JCI88876
Exley MA, Hand L, O’Shea D, Lynch L. Interplay between the immune system and adipose tissue in obesity. J Endocrinol. 2014;223:R41–8.
pubmed: 25228503
doi: 10.1530/JOE-13-0516
Ghilotti F, Bellocco R, Ye W, Adami HO, Trolle Lagerros Y. Obesity and risk of infections: results from men and women in the Swedish National March Cohort. Int J Epidemiol. 2019;48:1783–94.
pubmed: 31292615
Honce R, Schultz-Cherry S. Impact of obesity on influenza A virus pathogenesis, immune response, and evolution. Front Immunol. 2019;10:1071.
pubmed: 31134099
pmcid: 6523028
doi: 10.3389/fimmu.2019.01071
Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. Int J Obes. 2013;37:333–40.
doi: 10.1038/ijo.2012.62
Maier HE, Lopez R, Sanchez N, Ng S, Gresh L, Ojeda S, et al. Obesity increases the duration of influenza A virus shedding in adults. J Infect Dis. 2018;218:1378–82.
pubmed: 30085119
pmcid: 6151083
doi: 10.1093/infdis/jiy370
Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.
pubmed: 32444460
pmcid: 7243036
doi: 10.1136/bmj.m1985
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.
pubmed: 32640463
pmcid: 7611074
doi: 10.1038/s41586-020-2521-4
Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
pubmed: 32444366
pmcid: 7243801
doi: 10.1136/bmj.m1966
Kim J, Nam JH. Insight into the relationship between obesity-induced low-level chronic inflammation and COVID-19 infection. Int J Obes. 2020;44:1541–2.
doi: 10.1038/s41366-020-0602-y
Frasca D, Reidy L, Cray C, Diaz A, Romero M, Kahl K, et al. Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS ONE. 2021;16:e0245424.
pubmed: 33760825
pmcid: 7990309
doi: 10.1371/journal.pone.0245424
Frasca D, Reidy L, Romero M, Diaz A, Cray C, Kahl K, et al. The majority of SARS-CoV-2-specific antibodies in COVID-19 patients with obesity are autoimmune and not neutralizing. Int J Obes. 2022;46:427–32.
doi: 10.1038/s41366-021-01016-9
Gotzinger F, Santiago-Garcia B, Noguera-Julian A, Lanaspa M, Lancella L, Calo Carducci FI, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4:653–61.
pubmed: 32593339
pmcid: 7316447
doi: 10.1016/S2352-4642(20)30177-2
Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:458–64.
pubmed: 32298251
pmcid: 7755063
doi: 10.15585/mmwr.mm6915e3
CDC. Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7036e2.htm . Accessed February 3, 2022.
Dong Y, Mo X, Hu Y, Qi X, Jiang F, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145:e20200702.
pubmed: 32179660
doi: 10.1542/peds.2020-0702
Panahi L, Amiri M, Pouy S. Clinical characteristics of COVID-19 infection in newborns and pediatrics: a systematic review. Arch Acad Emerg Med. 2020;8:e50.
pubmed: 32440661
pmcid: 7212072
Fruhbeck G, Baker JL, Busetto L, Dicker D, Goossens GH, Halford JCG, et al. European association for the study of obesity position statement on the global COVID-19 pandemic. Obes Facts. 2020;13:292–6.
pubmed: 32340020
pmcid: 7250342
doi: 10.1159/000508082
Kumar S, Kelly AS. Review of childhood obesity: from epidemiology, etiology, and comorbidities to clinical assessment and treatment. Mayo Clin Proc. 2017;92:251–65.
pubmed: 28065514
doi: 10.1016/j.mayocp.2016.09.017
Alwarawrah Y, Kiernan K, MacIver NJ. Changes in nutritional status impact immune cell metabolism and function. Front Immunol. 2018;9:1055.
pubmed: 29868016
pmcid: 5968375
doi: 10.3389/fimmu.2018.01055
Wu CP, Adhi F, Highland K. Recognition and management of respiratory co-infection and secondary bacterial pneumonia in patients with COVID-19. Cleve Clin J Med. 2020;87:659–63.
pubmed: 32393593
doi: 10.3949/ccjm.87a.ccc015
Al Heialy S, Hachim MY, Senok A, Gaudet M, Abou Tayoun A, Hamoudi R, et al. Regulation of angiotensin-converting enzyme 2 in obesity: implications for COVID-19. Front Physiol. 2020;11:555039.
pubmed: 33071815
pmcid: 7531362
doi: 10.3389/fphys.2020.555039
Zhang F, Xiong Y, Wei Y, Hu Y, Wang F, Li G, et al. Obesity predisposes to the risk of higher mortality in young COVID-19 patients. J Med Virol. 2020;92:2536–42.
pubmed: 32437016
doi: 10.1002/jmv.26039
Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. Lancet. 2020;395:1544–5.
pubmed: 32380044
pmcid: 7196905
doi: 10.1016/S0140-6736(20)31024-2
Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21:e13128.
pubmed: 32845580
doi: 10.1111/obr.13128
Collaboration NCDRF. Rising rural body-mass index is the main driver of the global obesity epidemic in adults. Nature. 2019;569:260–4.
doi: 10.1038/s41586-019-1171-x
Popkin BM, Corvalan C, Grummer-Strawn LM. Dynamics of the double burden of malnutrition and the changing nutrition reality. Lancet. 2020;395:65–74.
pubmed: 31852602
doi: 10.1016/S0140-6736(19)32497-3
Albashir AAD. The potential impacts of obesity on COVID-19. Clin Med. 2020;20:e109–e13.
doi: 10.7861/clinmed.2020-0239
Muscogiuri G, Pugliese G, Barrea L, Savastano S, Colao A. Commentary: obesity: the “Achilles heel” for COVID-19? Metabolism. 2020;108:154251.
pubmed: 32353356
pmcid: 7184987
doi: 10.1016/j.metabol.2020.154251
Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020;1–8.
Eastment MC, Berry K, Locke E, Green P, O’Hare A, Crothers K, et al. BMI and outcomes of SARS-CoV-2 among US veterans. Obesity. 2021;29:900–8.
pubmed: 33336934
doi: 10.1002/oby.23111
Kim SY, Yoo DM, Min C, Wee JH, Kim JH, Choi HG. Analysis of mortality and morbidity in COVID-19 patients with obesity using clinical epidemiological data from the korean center for disease control & prevention. Int J Environ Res Public Health. 2020;17:24.
Wang J, Zhu L, Liu L, Zhao XA, Zhang Z, Xue L, et al. Overweight and obesity are risk factors of severe illness in patients with COVID-19. Obesity. 2020;28:2049–55.
pubmed: 32735706
doi: 10.1002/oby.22979
Breland JY, Wong MS, Steers WN, Yuan AH, Haderlein TP, Washington DL. BMI and risk for severe COVID-19 among veterans health administration patients. Obesity. 2021;29:825–8.
pubmed: 33403755
doi: 10.1002/oby.23121
Recalde M, Pistillo A, Fernandez-Bertolin S, Roel E, Aragon M, Freisling H, et al. Body mass index and risk of COVID-19 diagnosis, hospitalisation, and death: a cohort study of 2 524 926 Catalans. J Clin Endocrinol Metab. 2021;106:e5030–42.
pubmed: 34297116
Sales-Peres SHC, de Azevedo-Silva LJ, Bonato RCS, Sales-Peres MC, Pinto A, Santiago Jr JF. Coronavirus (SARS-CoV-2) and the risk of obesity for critically illness and ICU admitted: meta-analysis of the epidemiological evidence. Obes Res Clin Pract. 2020;14:389–97.
Onder G, Palmieri L, Vanacore N, Giuliano M, Brusaferro S. Italian National Institute of Health C-MG. Nonrespiratory complications and obesity in patients dying with COVID-19 in Italy. Obesity. 2021;29:20–3.
pubmed: 32812383
doi: 10.1002/oby.23007
Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16:341–2.
pubmed: 32327737
pmcid: 7187148
doi: 10.1038/s41574-020-0364-6
Gao F, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY, et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care. 2020;43:e72–e4.
pubmed: 32409499
doi: 10.2337/dc20-0682
Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020;28:1195–9.
pubmed: 32271993
doi: 10.1002/oby.22831
Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71:896–7.
pubmed: 32271368
doi: 10.1093/cid/ciaa415
Mahrooz A, Muscogiuri G, Buzzetti R, Maddaloni E. The complex combination of COVID-19 and diabetes: pleiotropic changes in glucose metabolism. Endocrine. 2021;72:317–25.
pubmed: 33886062
pmcid: 8060688
doi: 10.1007/s12020-021-02729-7
Epsi NJ, Richard SA, Laing ED, Fries AC, Millar E, Simons MP, et al. Clinical, immunological and virological SARS-CoV-2 phenotypes in obese and non-obese military health system beneficiaries. J Infect Dis. 2021;224:1462–72.
pubmed: 34331541
pmcid: 8385847
doi: 10.1093/infdis/jiab396
Yang Y, Ding L, Zou X, Shen Y, Hu D, Hu X, et al. Visceral adiposity and high intramuscular fat deposition independently predict critical illness in patients with SARS-CoV-2. Obesity. 2020;28:2040–8.
pubmed: 32677752
doi: 10.1002/oby.22971
Andrade FB, Gualberto A, Rezende C, Percegoni N, Gameiro J, Hottz ED. The weight of obesity in immunity from influenza to COVID-19. Front Cell Infect Microbiol. 2021;11:638852.
pubmed: 33816341
pmcid: 8011498
doi: 10.3389/fcimb.2021.638852
Busetto L, Bettini S, Fabris R, Serra R, Dal Pra C, Maffei P, et al. Obesity and COVID-19: an Italian snapshot. Obesity. 2020;28:1600–5.
pubmed: 32463545
doi: 10.1002/oby.22918
Malik VS, Ravindra K, Attri SV, Bhadada SK, Singh M. Higher body mass index is an important risk factor in COVID-19 patients: a systematic review and meta-analysis. Environ Sci Pollut Res Int. 2020;27:42115–23.
pubmed: 32710359
doi: 10.1007/s11356-020-10132-4
Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108:154262.
pubmed: 32422233
pmcid: 7228874
doi: 10.1016/j.metabol.2020.154262
Fresan U, Guevara M, Elia F, Albeniz E, Burgui C, Castilla J, et al. Independent role of severe obesity as a risk factor for COVID-19 hospitalization: a Spanish Population-Based Cohort Study. Obesity. 2021;29:29–37.
pubmed: 32885905
doi: 10.1002/oby.23029
Gao M, Piernas C, Astbury NM, Hippisley-Cox J, O’Rahilly S, Aveyard P, et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021;9:350–9.
pubmed: 33932335
pmcid: 8081400
doi: 10.1016/S2213-8587(21)00089-9
Battisti S, Pedone C, Napoli N, Russo E, Agnoletti V, Nigra SG, et al. Computed tomography highlights increased visceral adiposity associated with critical illness in COVID-19. Diabetes Care. 2020;43:e129–e30.
pubmed: 32753457
doi: 10.2337/dc20-1333
Watanabe M, Caruso D, Tuccinardi D, Risi R, Zerunian M, Polici M, et al. Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19. Metabolism. 2020;111:154319.
pubmed: 32712222
pmcid: 7377788
doi: 10.1016/j.metabol.2020.154319
Petersen A, Bressem K, Albrecht J, Thiess HM, Vahldiek J, Hamm B, et al. The role of visceral adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany. Metabolism. 2020;110:154317.
pubmed: 32673651
pmcid: 7358176
doi: 10.1016/j.metabol.2020.154317
Kara AA, Boncuoglu E, Kiymet E, Arikan KO, Sahinkaya S, Duzgol M, et al. Evaluation of predictors of severe-moderate COVID-19 infections at children: a review of 292 children. J Med Virol. 2021;93:6634–40.
pubmed: 34314067
doi: 10.1002/jmv.27237
Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20:669–77.
pubmed: 32240634
pmcid: 7158570
doi: 10.1016/S1473-3099(20)30243-7
Karakaya Molla G, Unal Uzun O, Koc N, Ozen Yesil B, Bayhan GI. Evaluation of nutritional status in pediatric patients diagnosed with Covid-19 infection. Clin Nutr ESPEN. 2021;44:424–8.
pubmed: 34330500
pmcid: 8110330
doi: 10.1016/j.clnesp.2021.04.022
Sandoval M, Nguyen DT, Vahidy FS, Graviss EA. Risk factors for severity of COVID-19 in hospital patients age 18-29 years. PLoS ONE. 2021;16:e0255544.
pubmed: 34329347
pmcid: 8323903
doi: 10.1371/journal.pone.0255544
Badedi M, Darraj H, Alnami AQ, Makrami A, Mahfouz MS, Alhazmi K, et al. Epidemiological and clinical characteristics of deceased COVID-19 patients. Int J Gen Med. 2021;14:3809–19.
pubmed: 34335047
pmcid: 8317935
doi: 10.2147/IJGM.S320713
Caballero B. Humans against obesity: who will win? Adv Nutr. 2019;10(suppl_1):S4–S9.
pubmed: 30721956
pmcid: 6363526
doi: 10.1093/advances/nmy055
Kanneganti TD, Dixit VD. Immunological complications of obesity. Nat Immunol. 2012;13:707–12.
pubmed: 22814340
doi: 10.1038/ni.2343
Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH, Gargiullo P, et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS ONE. 2010;5:e9694.
pubmed: 20300571
pmcid: 2837749
doi: 10.1371/journal.pone.0009694
Paich HA, Sheridan PA, Handy J, Karlsson EA, Schultz-Cherry S, Hudgens MG, et al. Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza A virus. Obesity. 2013;21:2377–86.
pubmed: 23512822
doi: 10.1002/oby.20383
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26:1017–32.
pubmed: 32651579
doi: 10.1038/s41591-020-0968-3
Kruglikov IL, Scherer PE. The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections. Obesity. 2020;28:1187–90.
pubmed: 32339391
doi: 10.1002/oby.22856
Gupte M, Boustany-Kari CM, Bharadwaj K, Police S, Thatcher S, Gong MC, et al. ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol. 2008;295:R781–8.
pubmed: 18650320
pmcid: 2536864
doi: 10.1152/ajpregu.00183.2008
Maurya R, Sebastian P, Namdeo M, Devender M, Gertler A. COVID-19 severity in obesity: leptin and inflammatory cytokine interplay in the link between high morbidity and mortality. Front Immunol. 2021;12:649359.
pubmed: 34220807
pmcid: 8250137
doi: 10.3389/fimmu.2021.649359
Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47:193–9.
pubmed: 19333547
doi: 10.1007/s00592-009-0109-4
Al-Benna S. Association of high level gene expression of ACE2 in adipose tissue with mortality of COVID-19 infection in obese patients. Obes Med. 2020;19:100283.
pubmed: 32835126
pmcid: 7368415
doi: 10.1016/j.obmed.2020.100283
Bellido V, Perez A. Inpatient hyperglycemia management and COVID-19. Diabetes Ther. 2021;12:121–32.
pubmed: 33278017
doi: 10.1007/s13300-020-00966-z
Martyn JA, Kaneki M, Yasuhara S. Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. Anesthesiology. 2008;109:137–48.
pubmed: 18580184
doi: 10.1097/ALN.0b013e3181799d45
Sarver DC, Wong GW. Obesity alters Ace2 and Tmprss2 expression in lung, trachea, and esophagus in a sex-dependent manner:Implications for COVID-19. Biochem Biophy Res Commun. 2021;538:92–6.
doi: 10.1016/j.bbrc.2020.10.066
Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Du P, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 2020;5:283.
pubmed: 33277466
pmcid: 7714896
doi: 10.1038/s41392-020-00426-x
Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020;75:2829–45.
pubmed: 32496587
doi: 10.1111/all.14429
Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest. 2011;121:2094–101.
pubmed: 21633177
pmcid: 3104761
doi: 10.1172/JCI45887
Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–84.
pubmed: 17200717
pmcid: 1716210
doi: 10.1172/JCI29881
Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005;46:2347–55.
pubmed: 16150820
doi: 10.1194/jlr.M500294-JLR200
Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta. 2014;1842:446–62.
pubmed: 23707515
doi: 10.1016/j.bbadis.2013.05.017
Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.
pubmed: 21252989
pmcid: 3518031
doi: 10.1038/nri2921
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80:607–13.
pubmed: 32283152
pmcid: 7194613
doi: 10.1016/j.jinf.2020.03.037
Muscogiuri G, Pugliese G, Laudisio D, Castellucci B, Barrea L, Savastano S, et al. The impact of obesity on immune response to infection: Plausible mechanisms and outcomes. Obes Rev. 2021;22:e13216.
pubmed: 33719175
doi: 10.1111/obr.13216
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–9.
pubmed: 32217835
pmcid: 7190990
doi: 10.1172/JCI137244
Bettini S, Bucca G, Sensi C, Dal Pra C, Fabris R, Vettor R, et al. Higher levels of C-reactive protein and ferritin in patients with overweight and obesity and SARS-CoV-2-related pneumonia. Obes Facts. 2021;14:543–9.
pubmed: 34482305
pmcid: 8450829
doi: 10.1159/000517851
Ghosh A, Gao L, Thakur A, Siu PM, Lai CWK. Role of free fatty acids in endothelial dysfunction. J Biomed Sci. 2017;24:50.
pubmed: 28750629
pmcid: 5530532
doi: 10.1186/s12929-017-0357-5
Rogero MM, Calder PC. Obesity, inflammation, toll-like receptor 4 and fatty acids. Nutrients. 2018;10:432.
pmcid: 5946217
doi: 10.3390/nu10040432
Zelova H, Hosek J. TNF-alpha signalling and inflammation: interactions between old acquaintances. Inflamm Res. 2013;62:641–51.
pubmed: 23685857
doi: 10.1007/s00011-013-0633-0
Nguyen M, Bourredjem A, Piroth L, Bouhemad B, Jalil A, Pallot G, et al. High plasma concentration of non-esterified polyunsaturated fatty acids is a specific feature of severe COVID-19 pneumonia. Sci Rep. 2021;11:10824.
pubmed: 34031519
pmcid: 8144366
doi: 10.1038/s41598-021-90362-9
Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight. 2020;5:e140327.
pmcid: 7453907
doi: 10.1172/jci.insight.140327
Brandao SCS, Ramos JOX, Dompieri LT, Godoi E, Figueiredo JL, Sarinho ESC, et al. Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities? Cytokine Growth Factor Rev. 2021;58:102–10.
pubmed: 32988728
doi: 10.1016/j.cytogfr.2020.09.002
Wei C, Wan L, Yan Q, Wang X, Zhang J, Yang X, et al. HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. Nat Metab. 2020;2:1391–400.
pubmed: 33244168
doi: 10.1038/s42255-020-00324-0
Cinti S, Graciotti L, Giordano A, Valerio A, Nisoli E. COVID-19 and fat embolism: a hypothesis to explain the severe clinical outcome in people with obesity. Int J Obes. 2020;44:1800–2.
doi: 10.1038/s41366-020-0624-5
Hotoleanu C. Association between obesity and venous thromboembolism. Med Pharm Rep. 2020;93:162–8.
pubmed: 32478322
pmcid: 7243888
Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, et al. Interleukin 1alpha: a comprehensive review on the role of IL-1alpha in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2021;20:102763.
pubmed: 33482337
doi: 10.1016/j.autrev.2021.102763
Walborn A, Hoppensteadt D, Syed D, Mosier M, Fareed J. Biomarker profile of sepsis-associated coagulopathy using biochip assay for inflammatory cytokines. Clin Appl Thromb Hemost. 2018;24:625–32.
pubmed: 28514870
doi: 10.1177/1076029617709084
Savla SR, Prabhavalkar KS, Bhatt LK. Cytokine storm associated coagulation complications in COVID-19 patients: pathogenesis and management. Expert Rev Anti Infect Ther. 2021;19:1397–413.
pubmed: 33832398
doi: 10.1080/14787210.2021.1915129
Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med. 2019;33:363–82.
pubmed: 30806496
pmcid: 6430926
doi: 10.1111/jvim.15454
Cabandugama PK, Gardner MJ, Sowers JR. The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. Med Clin North Am. 2017;101:129–37.
pubmed: 27884224
pmcid: 5125542
doi: 10.1016/j.mcna.2016.08.009
Akoumianakis I, Filippatos T. The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity. Obes Rev. 2020;21:e13077.
pubmed: 32567171
doi: 10.1111/obr.13077
Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected-obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17:135–49.
pubmed: 33479538
doi: 10.1038/s41574-020-00462-1
Williams PCM, Howard-Jones AR, Hsu P, Palasanthiran P, Gray PE, McMullan BJ, et al. SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. Pathology. 2020;52:801–8.
pubmed: 32888706
doi: 10.1016/j.pathol.2020.08.001
Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. J Am Med Assoc. 2020;323:2427–9.
doi: 10.1001/jama.2020.8707
Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19? J Microbiol Immunol Infect. 2020;53:371–2.
pubmed: 32147409
pmcid: 7102573
doi: 10.1016/j.jmii.2020.02.011
Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children’s hospital in New York City, New York. JAMA Pediatr. 2020;174:e202430.
pubmed: 32492092
doi: 10.1001/jamapediatrics.2020.2430
Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395:1771–8.
pubmed: 32410760
pmcid: 7220177
doi: 10.1016/S0140-6736(20)31103-X
Chou J, Platt CD, Habiballah S, Nguyen AA, Elkins M, Weeks S, et al. Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C). J Allergy Clin Immunol. 2021;148:732–8 e1.
pubmed: 34224783
pmcid: 8252701
doi: 10.1016/j.jaci.2021.06.024